- Home
- DOYU vs AVIR Comparison
DOYU vs AVIR Comparison
Compare DOYU & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DOYU | AVIR |
|---|---|---|
| Founded | 2014 | 2012 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 203.7M | 236.7M |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | DOYU | AVIR |
|---|---|---|
| Price | $6.80 | $3.57 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 1 | 1 |
| Target Price | ★ $7.00 | $6.00 |
| AVG Volume (30 Days) | 41.9K | ★ 380.2K |
| Earning Date | 11-20-2025 | 11-12-2025 |
| Dividend Yield | ★ 146.09% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $566,928,371.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.68 | $2.46 |
| 52 Week High | $16.99 | $4.02 |
Technical Indicators
Market Signals| Indicator | DOYU | AVIR |
|---|---|---|
| Relative Strength Index (RSI) | 48.63 | 64.57 |
| Support Level | $6.73 | $3.11 |
| Resistance Level | $7.14 | $3.72 |
| Average True Range (ATR) | 0.22 | 0.12 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 45.45 | 74.80 |
Price Performance
Historical ComparisonAbout DOYU DouYu International Holdings Limited ADS
DouYu International Holdings Ltd is a game-centric live streaming platform in China and a pioneer in the eSports value chain. The company operates its platform on both PC and mobile apps, through which users can enjoy immersive and interactive games and entertainment live streaming. It generates revenues through live streaming and advertisement.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).